Synaptogenix, Inc. (SNPX)

NASDAQ: SNPX · Real-Time Price · USD
3.000
-0.010 (-0.33%)
Oct 2, 2024, 4:00 PM EDT - Market closed
-0.33%
Market Cap 3.94M
Revenue (ttm) n/a
Net Income (ttm) -3.45M
Shares Out 1.31M
EPS (ttm) -3.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,243
Open 2.970
Previous Close 3.010
Day's Range 2.970 - 3.140
52-Week Range 2.720 - 10.500
Beta 1.44
Analysts Strong Buy
Price Target 14.00 (+366.67%)
Earnings Date Nov 12, 2024

About SNPX

Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 5
Stock Exchange NASDAQ
Ticker Symbol SNPX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for SNPX stock is "Strong Buy" and the 12-month stock price forecast is $14.0.

Price Target
$14.0
(366.67% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Synaptogenix Announces $5.0 Million Financing

NEW YORK , Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disor...

21 days ago - PRNewsWire

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in the treatment of neurodegenerative diseases NEW YORK , July 18, 2024 /PRN...

2 months ago - PRNewsWire

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , June 26, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synapto...

3 months ago - PRNewsWire

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways NEW YORK , May 7, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) (...

5 months ago - PRNewsWire

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

NEW YORK , April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disor...

5 months ago - PRNewsWire

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Common stock will begin trading on split-adjusted basis on April 5, 2024 NEW YORK , April 3, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging bioph...

6 months ago - PRNewsWire

Synaptogenix President Daniel L. Alkon, M.D.

Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK , Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SN...

10 months ago - PRNewsWire

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Presenters, including Nobel Laureate in Medicine, to discuss innovative treatments for neurodegeneration Company to feature lead therapeutic's statistically significant benefits, p < 0.007, for severe...

10 months ago - PRNewsWire

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Acquires 25% stake in Cannasoul Analytics for up to $4 million to support R&D for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications Partners to drive development and com...

11 months ago - PRNewsWire

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK , Sept. 26, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: S...

1 year ago - PRNewsWire

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Positive changes in ALS gene expression and increased cellular viability met with statistical significance of p

1 year ago - PRNewsWire

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Study will evaluate drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients NEW YORK , July 19, 2023 /PRNewswire/ -- Synaptogenix,...

1 year ago - PRNewsWire

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Phase 2 Bryostatin-1 Severe Cohort secondary and exploratory endpoint data selected by independent committee for presentation NEW YORK , July 13, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX)...

1 year ago - PRNewsWire

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Announces encouraging secondary endpoint results from NIH-sponsored Phase 2 clinical trial of Bryostatin-1 in advanced Alzheimer's disease patients Maintains strong financial position with approximate...

1 year ago - PRNewsWire

5 Health Care Stocks That Are Diving - And May Rally

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: FATEIPSCNVOSTECH
1 year ago - Benzinga

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

NEW YORK , Dec. 16, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegene...

1 year ago - PRNewsWire

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in Alzheimer's disease for the current quarter. Preclinical work showed that its drug candidate Bryostatin-1 has s...

1 year ago - Seeking Alpha

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Topline data from NIH-supported Phase 2 clinical trial for advanced AD patients expected during the current quarter NEW YORK , Nov. 18, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synapto...

2 years ago - PRNewsWire

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Synaptogenix is one of few companies developing therapeutics for advanced Alzheimer's disease (AD); no such drug has received FDA approval to date Topline data from NIH-supported Phase 2 clinical tria...

2 years ago - PRNewsWire

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Synaptogenix expecting data from its Phase 2 clinical trial of Bryostatin-1 for advanced Alzheimer's disease in fourth quarter 2022 NEW YORK , Sept. 28, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq...

2 years ago - PRNewsWire

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

NEW YORK , Aug. 12, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disord...

2 years ago - PRNewsWire

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK , July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company develo...

2 years ago - PRNewsWire

Synaptogenix Announces Corporate Update Conference Call

NEW YORK , July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disord...

2 years ago - PRNewsWire

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Dose optimization prepares the Company for its next phase of Bryostatin clinical development Company expects to announce topline data from its NIH sponsored Phase 2 clinical study during the fourth qu...

2 years ago - PRNewsWire

Synaptogenix to Present at the Cell Symposium

NEW YORK , May 17, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegener...

2 years ago - PRNewsWire